844 related articles for article (PubMed ID: 19405003)
1. Development and validation of a composite disease activity score for juvenile idiopathic arthritis.
Consolaro A; Ruperto N; Bazso A; Pistorio A; Magni-Manzoni S; Filocamo G; Malattia C; Viola S; Martini A; Ravelli A;
Arthritis Rheum; 2009 May; 61(5):658-66. PubMed ID: 19405003
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of the Disease Activity Score-28 and Juvenile Arthritis Disease Activity Score in the juvenile idiopathic arthritis].
Capela RC; Corrente JE; Magalhães CS
Rev Bras Reumatol; 2015; 55(1):31-6. PubMed ID: 25440705
[TBL] [Abstract][Full Text] [Related]
3. Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting.
Nordal EB; Zak M; Aalto K; Berntson L; Fasth A; Herlin T; Lahdenne P; Nielsen S; Peltoniemi S; Straume B; Rygg M
Ann Rheum Dis; 2012 Jul; 71(7):1122-7. PubMed ID: 22258487
[TBL] [Abstract][Full Text] [Related]
4. Performance of rheumatoid arthritis disease activity measures and juvenile arthritis disease activity scores in polyarticular-course juvenile idiopathic arthritis: Analysis of their ability to classify the American College of Rheumatology pediatric measures of response and the preliminary criteria for flare and inactive disease.
Ringold S; Bittner R; Neogi T; Wallace CA; Singer NG
Arthritis Care Res (Hoboken); 2010 Aug; 62(8):1095-102. PubMed ID: 20506561
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI
Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
[TBL] [Abstract][Full Text] [Related]
6. Interpretation of the Juvenile Arthritis Disease Activity Score: responsiveness, clinically important differences and levels of disease activity in prospective cohorts of patients with juvenile idiopathic arthritis.
Bulatović Calasan M; de Vries LD; Vastert SJ; Heijstek MW; Wulffraat NM
Rheumatology (Oxford); 2014 Feb; 53(2):307-12. PubMed ID: 24162034
[TBL] [Abstract][Full Text] [Related]
7. Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis.
Swart JF; van Dijkhuizen EHP; Wulffraat NM; de Roock S
Ann Rheum Dis; 2018 Mar; 77(3):336-342. PubMed ID: 29138257
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
[TBL] [Abstract][Full Text] [Related]
9. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score.
Consolaro A; Bracciolini G; Ruperto N; Pistorio A; Magni-Manzoni S; Malattia C; Pederzoli S; Davì S; Martini A; Ravelli A;
Arthritis Rheum; 2012 Jul; 64(7):2366-74. PubMed ID: 22231288
[TBL] [Abstract][Full Text] [Related]
10. Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score.
Consolaro A; Ruperto N; Bracciolini G; Frisina A; Gallo MC; Pistorio A; Verazza S; Negro G; Gerloni V; Goldenstein-Schainberg C; Sztajnbok F; Wulffraat NM; Martini A; Ravelli A;
Ann Rheum Dis; 2014 Jul; 73(7):1380-3. PubMed ID: 24347571
[TBL] [Abstract][Full Text] [Related]
11. Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: a secondary analysis of clinical trial data from children with polyarticular-course juvenile idiopathic arthritis.
Ringold S; Chon Y; Singer NG
Arthritis Rheum; 2009 Dec; 60(12):3776-83. PubMed ID: 19950286
[TBL] [Abstract][Full Text] [Related]
12. Development and initial validation of composite parent- and child-centered disease assessment indices for juvenile idiopathic arthritis.
Consolaro A; Ruperto N; Pistorio A; Lattanzi B; Solari N; Galasso R; Pederzoli S; Varnier GC; Dolezalova P; Alessio M; Burgos-Vargas R; Vesely R; Martini A; Ravelli A;
Arthritis Care Res (Hoboken); 2011 Sep; 63(9):1262-70. PubMed ID: 21618454
[TBL] [Abstract][Full Text] [Related]
13. Definition of improvement in juvenile idiopathic arthritis using the juvenile arthritis disease activity score.
Horneff G; Becker I
Rheumatology (Oxford); 2014 Jul; 53(7):1229-34. PubMed ID: 24599918
[TBL] [Abstract][Full Text] [Related]
14. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.
Funk RS; Chan MA; Becker ML
Pharmacotherapy; 2017 Jun; 37(6):700-711. PubMed ID: 28475276
[TBL] [Abstract][Full Text] [Related]
15. Responsiveness of clinical measures to flare of disease activity in juvenile idiopathic arthritis.
Magni-Manzoni S; Cugno C; Pistorio A; Garay S; Tsitsami E; Gasparini C; Viola S; Ruperto N; Martini A; Ravelli A
Clin Exp Rheumatol; 2005; 23(3):421-5. PubMed ID: 15971436
[TBL] [Abstract][Full Text] [Related]
16. American College of Rheumatology/European League Against Rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints.
Kaneko Y; Kondo H; Takeuchi T
J Rheumatol; 2013 Aug; 40(8):1254-8. PubMed ID: 23772077
[TBL] [Abstract][Full Text] [Related]
17. Description of active joint count trajectories in juvenile idiopathic arthritis.
Berard RA; Tomlinson G; Li X; Oen K; Rosenberg AM; Feldman BM; Yeung RS; Bombardier C
J Rheumatol; 2014 Dec; 41(12):2466-73. PubMed ID: 25274882
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.
van Rossum MA; van Soesbergen RM; Boers M; Zwinderman AH; Fiselier TJ; Franssen MJ; ten Cate R; van Suijlekom-Smit LW; Wulffraat NM; van Luijk WH; Oostveen JC; Kuis W; Dijkmans BA;
Ann Rheum Dis; 2007 Nov; 66(11):1518-24. PubMed ID: 17491099
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
Kimura Y; Schanberg LE; Tomlinson GA; Riordan ME; Dennos AC; Del Gaizo V; Murphy KL; Weiss PF; Natter MD; Feldman BM; Ringold S;
Arthritis Rheumatol; 2021 Oct; 73(10):1898-1909. PubMed ID: 34105312
[TBL] [Abstract][Full Text] [Related]
20. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
